These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16680752)

  • 1. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
    Lazarevic V; Golovleva I; Nygren I; Wahlin A
    Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
    [No Abstract]   [Full Text] [Related]  

  • 2. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
    Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
    Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the dose of STI-571 needed to induce a molecular remission in chronic myeloid leukemia?
    Ruiz-Argüelles GJ
    Haematologica; 2002 Mar; 87(3):ELT15. PubMed ID: 11869961
    [No Abstract]   [Full Text] [Related]  

  • 4. Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation--durable complete remission following imatinib therapy.
    Dufva IH; Karle H; Brondum-Nielsen K; Andersen MK; Madsen HO; Johnsen HE
    Leukemia; 2005 Apr; 19(4):671-3. PubMed ID: 15703782
    [No Abstract]   [Full Text] [Related]  

  • 5. [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
    Ajima A; Takayama N; Hasegawa Y; Kojima H; Nagasawa T
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1997-9. PubMed ID: 14650975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia].
    Yamaguchi M; Konishi I
    Rinsho Ketsueki; 2003 Apr; 44(4):254-6. PubMed ID: 12784659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
    Mahon FX; Molimard M
    Leuk Res; 2009 Aug; 33(8):1147-8; author reply 1149-50. PubMed ID: 19395027
    [No Abstract]   [Full Text] [Related]  

  • 8. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission.
    Carella AM; Lerma E
    Ann Hematol; 2007 Oct; 86(10):749-52. PubMed ID: 17576558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis.
    Ozdemir E; Koc Y; Kansu E
    Am J Hematol; 2006 Jun; 81(6):474. PubMed ID: 16680756
    [No Abstract]   [Full Text] [Related]  

  • 10. [Trends in molecular targeting therapeutics for chronic myeloid leukemia].
    Nagai T
    Rinsho Ketsueki; 2007 Oct; 48(10):1360-9. PubMed ID: 17933121
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
    Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
    Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
    Cho BS; Kim HJ; Lee S; Eom KS; Min WS; Lee JW; Kim CC
    Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
    Kiguchi T; Tauchi T; Ohyashiki K
    Rinsho Ketsueki; 2009 Jan; 50(1):52-4. PubMed ID: 19225231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 15. Monitoring of plasma imatinib concentration for the effective treatment of CML patients.
    Tsutsumi Y; Kanamori H; Yamato H; Ehira N; Miura T; Kawamura T; Obara S; Tanaka J; Asaka M; Imamura M; Masauzi N
    Leuk Res; 2004 Oct; 28(10):1117-8. PubMed ID: 15289027
    [No Abstract]   [Full Text] [Related]  

  • 16. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
    Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
    Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
    Singh T; Casson C
    Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up.
    Breccia M; Stagno F; Vigneri P; Latagliata R; Cannella L; Del Fabro V; Di Raimondo F; Alimena G
    Am J Hematol; 2010 May; 85(5):375-7. PubMed ID: 20306543
    [No Abstract]   [Full Text] [Related]  

  • 19. Residual disease in chronic myeloid leukemia after induction of molecular remission.
    Lange T; Niederwieser DW; Deininger MW
    N Engl J Med; 2003 Oct; 349(15):1483-4. PubMed ID: 14534349
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.
    Pompetti F; Spadano A; Sau A; Mennucci A; Russo R; Catinella V; Franchi PG; Calabrese G; Palka G; Fioritoni G; Iacone A
    Leuk Res; 2007 Apr; 31(4):563-7. PubMed ID: 16916543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.